IMS - Mercado Farmac?utico - Hasta MAYO 2011
Ventas de Mercado (Fuente: IMS Health)
NORTH AMERICA $246.8 billion up 4%
EUROPE $109.9 billion up 2%
JAPAN $92.0 billion up 3%
CHINA (hospital) $35.8 billion up 19%
LATIN AMERICA (TOP 4) $37.6 billion
Espa?a sigue decreciendo, esta vez un 2.
IMS Mercado Farmac?utico ENERO 2011
NORTH AMERICA $244.6 billion up 3%
EUROPE (TOP 5) $107.3 billion up 3%
JAPAN (including hospitals) $86.8 billion up 1%
CHINA (hospital) $32.8 billion up 22%
LATIN AMERICA (TOP 4) $36.0 billion
AUSTRALIA/NZ $9.5 billion up 5%
Mercado Farmac?utico -IMS Health (MAY2010)
Actualizaci?n por parte de IMS Health de las ventas y crecimiento del mercado farmac?utico:
NORTH AMERICA $240.6 billion up 6%
U.S.A. $221.8 billion up 6%
CANADA $18.8 billion up 7%
EUROPE (TOP 5) $111.5 billion up 3%
GERMANY $36.1 billion up 4%
IMS Health - Mercado Farmac?utico - APR 2010
IMS acaba de enviar el reporte mensual de abril sobre el estado del sector farmac?utico a nivel mundial. Entre todos los mercados, destaca China que crece un 28% y se observa un enlentecimiento del resto.
Sales Through Retail Pharmacies (Twelve months to April 2010)*
NORTH AMERICA $239.5 billion up 6%
U.S.A. $221 billion up 6%
CANADA $18.5 billion up 7%
EUROPE (TOP 5) $112.1 billion up 2%
GERMANY $36.3 billion up 4%
FRANCE $29.7 billion up 1%
ITALY $16.7 billion up 0%
SPAIN $15.4 billion up 3%
UK $14 billion up 3%
JAPAN (including hospitals) $81.3 billion up 5%
CHINA (hospital) $26.8 billion up 28%
LATIN AMERICA (TOP 4) $31.6 billion
BRAZIL $15 billion up 18%
MEXICO $7.4 billion up 1%
VENEZUELA $5.8 billion up 29%
ARGENTINA $3.5 billion up 23%
AUSTRALIA/NZ $8.8 billion up 8%
The top 5 therapy classes at ATC3 level in the 12 months to April 2010 were:
1. C10A – Cholesterol & trigly. regulators
2. A2B - Antiulcerants
3. N6A – Antidepressants & mood stabilisers
4. N5A - Antipsychotics
5. C9C – Angioten-II Antag, Plain
The top 5 products in the 12 months to April 2010 were:
1. Lipitor
2. Plavix
3. Nexium
4. Seretide
5. Crestor
The top 5 corporations in the 12 months to April 2010 were:
1. Pfizer
2. Merck & Co
3. Novartis
4. AstraZeneca
5. GlaxoSmithKline
Article Details
